Cytosorbents Corporation (CTSO) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
CTSO Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Cytosorbents Corporation (CTSO) trades at a price-to-earnings ratio of -1.6x, with a stock price of $0.61 and trailing twelve-month earnings per share of $-0.15.
Compared to the Healthcare sector median P/E of 22.3x, CTSO trades at a 107% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, CTSO trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CTSO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CTSO P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $3B | 4186.1 | - | +101%Best | |
| $2B | 42.8 | 2.21 | +31% | |
| $56B | 26.3 | 1.59Best | -1% | |
| $100B | 21.6Lowest | - | +31% | |
| $84B | 29.2 | - | +55% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See CTSO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTSO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTSO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCTSO — Frequently Asked Questions
Quick answers to the most common questions about buying CTSO stock.
Is CTSO stock overvalued or undervalued?
CTSO current P/E: -1.6x. 5-year average P/E: N/A. Percentile: N/A.
How does CTSO's valuation compare to peers?
Cytosorbents Corporation P/E of -1.6x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is CTSO's PEG ratio?
CTSO PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.